HPV test brings Digene to profit:
This article was originally published in Clinica
Executive Summary
Digene (Gaithersburg, Maryland) has reported its first profitable quarter as it saw strong growth in sales of its human papillomavirus (HPV) test. The test gained approval in the US as a primary screening tool for cervical cancer five months ago. The company reported net income of $0.3m in the fourth quarter ended June 30, on sales up by 50% to $19.1m. HPV test sales rose by 68% to $16m. The company is building up its sales presence in Europe and elsewhere and expects 2004 full-year sales to reach $90-95m. 2003 sales were $63m (+29%), with a net loss of $4.3m.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.